Skip to Content

Item 9 Labs Corp INLB

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

INLB is trading at a 498% premium.
Price
$0.00
Fair Value
$2.63
Uncertainty
Extreme
1-Star Price
$4.16
5-Star Price
$9.20
Economic Moat
Dmhn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INLB is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.05
Bid/Ask
$0.00 / $0.00
Market Cap
$102.36
Volume/Avg
2,013 / 2.7 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Total Number of Employees
104

Valuation

Metric
INLB
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
INLB

Financial Strength

Metric
INLB
Quick Ratio
0.02
Current Ratio
0.06
Interest Coverage
−2.37
Quick Ratio
INLB

Profitability

Metric
INLB
Return on Assets (Normalized)
−16.83%
Return on Equity (Normalized)
−30.95%
Return on Invested Capital (Normalized)
−12.76%
Return on Assets
INLB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YwvtgvfxrcHyql$83.1 Bil
Merck KGaA ADR
MKKGY
CffhjjjzftHsbjm$73.3 Bil
Haleon PLC ADR
HLN
CfmlzrqwqMmsb$39.7 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
QcpwsrrlQzmf$19.0 Bil
Viatris Inc
VTRS
BmnqqgdnwGprp$14.1 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
RgpjkywNxlt$13.2 Bil
Catalent Inc
CTLT
WcngfjkhnNtzxtj$10.5 Bil
Perrigo Co PLC
PRGO
SwlkpmbpxRcdxg$3.8 Bil
Prestige Consumer Healthcare Inc
PBH
NmdyyqktTyrpzrr$3.6 Bil
Curaleaf Holdings Inc
CURLF
ZspdncqyNvjz$3.2 Bil

Sponsor Center